구조모아 (StructureMoa)항암 chemical structure spider web
방문향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 6건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Dupixent (dupilumab) | — | Active, not recruiting | Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment; Frequency of reasons for dupilumab treatment modifications with the description of the modified treatment; Proportion of patients who discontinued dupilumab; Frequency of reasons for dupilumab treatment discontinuation; Proportion of patients hospitalized due to PN | 신뢰 높음 | NCT05991323 |
| 2026년 9월 | Dupixent (dupilumab) | Phase 1 | Recruiting | Pharmacokinetics Endpoint; Pharmacokinetics Endpoint; Pharmacokinetics Endpoint | 신뢰 높음 | NCT07411755 |
| 2026년 9월 | Dupixent (dupilumab) | Phase 4 | Recruiting | Change in mucociliary clearance (MCC) rate | 보통 | NCT04743791 |
| 2026년 9월 | Tezspire (tezepelumab) | Phase 1 | Not yet recruiting | Pharmacokinetics Endpoint; Pharmacokinetics Endpoint | 신뢰 높음 | NCT07327697 |
| 2026년 9월 | Dupixent (dupilumab) | — | Active, not recruiting | Identification of epigenetic biomarkers and pathogenic viruses | 신뢰 높음 | NCT05857228 |
| 2026년 9월 | Dupixent (dupilumab) | Phase 1 | Recruiting | Pharmacokinetic (PK) parameter in serum: Cmax of dupilumab; PK parameter in serum: AUClast of dupilumab | 보통 | NCT07646548 |
Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment; Frequency of reasons for dupilumab treatment modifications with the description of the modified treatment; Proportion of patients who discontinued dupilumab; Frequency of reasons for dupilumab treatment discontinuation; Proportion of patients hospitalized due to PN
NCT05991323Pharmacokinetics Endpoint; Pharmacokinetics Endpoint; Pharmacokinetics Endpoint
NCT07411755Change in mucociliary clearance (MCC) rate
NCT04743791Pharmacokinetics Endpoint; Pharmacokinetics Endpoint
NCT07327697Identification of epigenetic biomarkers and pathogenic viruses
NCT05857228Pharmacokinetic (PK) parameter in serum: Cmax of dupilumab; PK parameter in serum: AUClast of dupilumab
NCT07646548향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.
향후 6개월 catalyst 6건 · 타깃·모달리티 분포
활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 9월 | Dupixent (dupilumab) | — | Active, not recruiting | Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment; Frequency of reasons for dupilumab treatment modifications with the description of the modified treatment; Proportion of patients who discontinued dupilumab; Frequency of reasons for dupilumab treatment discontinuation; Proportion of patients hospitalized due to PN | 신뢰 높음 | NCT05991323 |
| 2026년 9월 | Dupixent (dupilumab) | Phase 1 | Recruiting | Pharmacokinetics Endpoint; Pharmacokinetics Endpoint; Pharmacokinetics Endpoint | 신뢰 높음 | NCT07411755 |
| 2026년 9월 | Dupixent (dupilumab) | Phase 4 | Recruiting | Change in mucociliary clearance (MCC) rate | 보통 | NCT04743791 |
| 2026년 9월 | Tezspire (tezepelumab) | Phase 1 | Not yet recruiting | Pharmacokinetics Endpoint; Pharmacokinetics Endpoint | 신뢰 높음 | NCT07327697 |
| 2026년 9월 | Dupixent (dupilumab) | — | Active, not recruiting | Identification of epigenetic biomarkers and pathogenic viruses | 신뢰 높음 | NCT05857228 |
| 2026년 9월 | Dupixent (dupilumab) | Phase 1 | Recruiting | Pharmacokinetic (PK) parameter in serum: Cmax of dupilumab; PK parameter in serum: AUClast of dupilumab | 보통 | NCT07646548 |
Frequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment; Frequency of reasons for dupilumab treatment modifications with the description of the modified treatment; Proportion of patients who discontinued dupilumab; Frequency of reasons for dupilumab treatment discontinuation; Proportion of patients hospitalized due to PN
NCT05991323Pharmacokinetics Endpoint; Pharmacokinetics Endpoint; Pharmacokinetics Endpoint
NCT07411755Change in mucociliary clearance (MCC) rate
NCT04743791Pharmacokinetics Endpoint; Pharmacokinetics Endpoint
NCT07327697Identification of epigenetic biomarkers and pathogenic viruses
NCT05857228Pharmacokinetic (PK) parameter in serum: Cmax of dupilumab; PK parameter in serum: AUClast of dupilumab
NCT07646548